Back to Search Start Over

Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE.

Authors :
Thariat J
Schouman T
Brouchet A
Sarini J
Miller RC
Reychler H
Ray-Coquard I
Italiano A
Verite C
Sohawon S
Bompas E
Dassonville O
Salas S
Aldabbagh K
Maingon P
de La MotteRouge T
Kurtz JE
Usseglio J
Kerbrat P
Raoul G
Lotz JP
Bar-Sela G
Brugières L
Chaigneau L
Saada E
Odin G
Marcy PY
Thyss A
Julieron M
Source :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2013 Mar; Vol. 24 (3), pp. 824-31. Date of Electronic Publication: 2012 Nov 06.
Publication Year :
2013

Abstract

Background: Mandibular osteosarcomas (MOS) mostly affect young adults. Their treatment is extrapolated from that of extragnathic osteosarcomas.<br />Material and Methods: A retrospective multicooperative group study was conducted to determine the impact of chemotherapy, adjuvant radiation therapy and surgery on outcomes and to identify prognostic factors. This ethical committee-approved study included a centralized review of histology slides and operative reports.<br />Results: Of 111 patients, 58.6% were male, median age 35 years (13%, ≤18 years). Histology was osteoblastic, chondroblastic, fibroblastic, conventional not otherwise specified and others in 39.6%, 30.6%, 8.1%, 12.6% and 8.0%, respectively. Pathological World Health Organisation grades were low, intermediate and high grade in 6.4%, 11.8% and 81.8%, respectively. Surgery was carried out for 94.5% of patients. Neoadjuvant chemotherapy (mixed protocols) was carried out in 93.1% of patients. Postoperative chemotherapy and radiotherapy were carried out in 54.7% and 23.8%, respectively. Median follow-up was 59.6 months (range). Five-year local control, metastasis-free, disease-free and overall survival rates were 64.6%, 68.9%, 53.2% and 69.2%, respectively. Survival was significantly associated with age, tumor size and surgery. Wide surgery with clear margins and free flap reconstruction was the strongest prognostic factor. Neoadjuvant chemotherapy improved disease-free and metastatic-free survival and increased clear margins rates from 50% to 68%. Intermediate grades behaved like high grades in terms of metastatic-free and disease-free survival.<br />Conclusion: This homogeneous series is the largest to date and emphasizes the major impact of clear margins and multidisciplinary management. Neoadjuvant chemotherapy improves disease-free survival and should be recommended for both high and intermediate grade MOS.

Details

Language :
English
ISSN :
1569-8041
Volume :
24
Issue :
3
Database :
MEDLINE
Journal :
Annals of oncology : official journal of the European Society for Medical Oncology
Publication Type :
Academic Journal
Accession number :
23131392
Full Text :
https://doi.org/10.1093/annonc/mds507